Prelude Capital Management’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Prelude Capital Management’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-1,100	Closed	-$50K	–	1889
2016 Q3	$50K	Sell	1,100 -500	-31%	-$20.1K	0.01%	1045
2016 Q2	$64K	Hold	1,600	–	–	0.01%	917
2016 Q1	$56K	Buy	1,600 +300	+23%	+$11K	0.01%	949
2015 Q4	$56K	Buy	+1,300	New	+$65.1K	0.01%	1018
2015 Q1	–	Sell	-1,100	Closed	-$42K	–	2293
2014 Q4	$42K	Hold	1,100	–	–	0.01%	1334
2014 Q3	$39K	Buy	+1,100	New	+$32.3K	0.01%	1481

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

ECP

Elk Creek Partners Denver, Colorado $582M AUM 10.23% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Prelude Capital Management's BSTC Position: Q4 2016 in Review

Prelude Capital Management sold out of BioSpecifics Technologies Corp. (BSTC) in Q4 2016, closing a stake of 1,100 shares — an estimated $50K sold.

Prelude Capital Management first reported a position in BSTC in Q3 2014 and held it in 6 quarters. The position peaked at $64K in Q2 2016. 96 funds tracked by Wall St. Rank hold BSTC as of Q4 2016.

Prelude Capital Management reported no remaining BioSpecifics Technologies Corp. position as of Q4 2016 after selling out during the quarter.
Prelude Capital Management sold 1,100 BioSpecifics Technologies Corp. shares in Q4 2016, an estimated $50K.
Prelude Capital Management first reported a position in BioSpecifics Technologies Corp. in Q3 2014 and held it in 6 quarters.
Prelude Capital Management's BioSpecifics Technologies Corp. position peaked at $64K in Q2 2016.
96 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q4 2016.

Based on Prelude Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.